Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
An Immunological and Microbial Analysis of Crohn’s Disease Patients after Repeated Fecal Microbial Transplants
FY 2013-14
Summary
Crohn’s disease is characterized by chronic intestinal inflammation causing abdominal pain, diarrhea, intestinal bleeding, and weight loss and is becoming more common throughout the world. CD occurs in genetically-predisposed individuals who are exposed to microbial, dietary, and environmental triggers. Patients with Crohn’s disease (CD) exhibit a “dysbiosis” of gut microbiota with reduced microbial diversity as compared with healthy individuals. This has led to the hypothesis that CD occurs due to an imbalance between pathogenic and protective bacterial taxa that results in an increased intraluminal generation of pro-inflammatory molecules by specific microbial groups that trigger dysregulated innate and adaptive immune responses. Thus, therapy aimed at correcting the imbalance within the gut microbiota may improve disease in CD patients by increasing microbial diversity and altering immune responses elicited by specific microbial products of pathogenic bacteria, thus ultimately limiting and suppressing disease activity.
Fecal microbiota transplantation (FMT) has been used very successfully to treat recurrent Clostridium difficle colitis with an overall cure rate of over 80% after one infusion. We have an active FMT program at the University of Alberta and have performed over 60 FMT to date, with a success rate of 95%. However, in patients with CD, results do not seem to be as long lasting as that seen in patients with C. difficile colitis. Manipulation of the intestinal microbiota is a potential therapeutic target for CD patients, but studies are required to determine if repeated FMT can maintain the response. A pilot study will be carried out to investigate the potential efficacy of FMT for CD by determining if repeated infusions can improve clinical disease and maintain the stability of transplanted microbiota in patients with mild to moderate CD. The hypothesis to be tested in this research project is that an immune response to FMT in CD patients acts to destabilize the transplanted microbiota.
This study will enroll 20 patients with active CD to receive serial FMT therapy at the University of Alberta Hospital (UAH) for a period of 12 weeks. Patients who have CD and are followed at the Zeidler Ledcor Center will be approached for potential recruitment if they fulfill all inclusion and exclusion criteria. Efficacy of treatment will be determined by endoscopic assessment by Dr. Dina Kao. At the time of endoscopy, biopsies will be obtained for analysis of host immune response and microbial composition. Information from these studies will be used to define the predominate immune response in the mucosa that occurs following FMT and how it modulates microbial composition. Together, these data will provide important insights into the mechanisms of disease recurrence/remission by making direct correlations with immune responses and microbial populations on a longitudinal basis in individuals receiving sequential FMT, allowing for each individual to act as their own control.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
312001
Name
Millan Braden T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
An Immunological and Microbial Analysis of Crohn’s Disease Patients after Repeated Fecal Microbial Transplants
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crohn'S Disease; Fecal Microbial Transplantation; Gastrointestinal Diseases; Inflammatory Bowel Disease; Innovative; Treatment; Trial
Abstract
Crohn’s disease is characterized by chronic intestinal inflammation causing abdominal pain, diarrhea, intestinal bleeding, and weight loss and is becoming more common throughout the world. CD occurs in genetically-predisposed individuals who are exposed to microbial, dietary, and environmental triggers. Patients with Crohn’s disease (CD) exhibit a “dysbiosis” of gut microbiota with reduced microbial diversity as compared with healthy individuals. This has led to the hypothesis that CD occurs due to an imbalance between pathogenic and protective bacterial taxa that results in an increased intraluminal generation of pro-inflammatory molecules by specific microbial groups that trigger dysregulated innate and adaptive immune responses. Thus, therapy aimed at correcting the imbalance within the gut microbiota may improve disease in CD patients by increasing microbial diversity and altering immune responses elicited by specific microbial products of pathogenic bacteria, thus ultimately limiting and suppressing disease activity.
Fecal microbiota transplantation (FMT) has been used very successfully to treat recurrent Clostridium difficle colitis with an overall cure rate of over 80% after one infusion. We have an active FMT program at the University of Alberta and have performed over 60 FMT to date, with a success rate of 95%. However, in patients with CD, results do not seem to be as long lasting as that seen in patients with C. difficile colitis. Manipulation of the intestinal microbiota is a potential therapeutic target for CD patients, but studies are required to determine if repeated FMT can maintain the response. A pilot study will be carried out to investigate the potential efficacy of FMT for CD by determining if repeated infusions can improve clinical disease and maintain the stability of transplanted microbiota in patients with mild to moderate CD. The hypothesis to be tested in this research project is that an immune response to FMT in CD patients acts to destabilize the transplanted microbiota.
This study will enroll 20 patients with active CD to receive serial FMT therapy at the University of Alberta Hospital (UAH) for a period of 12 weeks. Patients who have CD and are followed at the Zeidler Ledcor Center will be approached for potential recruitment if they fulfill all inclusion and exclusion criteria. Efficacy of treatment will be determined by endoscopic assessment by Dr. Dina Kao. At the time of endoscopy, biopsies will be obtained for analysis of host immune response and microbial composition. Information from these studies will be used to define the predominate immune response in the mucosa that occurs following FMT and how it modulates microbial composition. Together, these data will provide important insights into the mechanisms of disease recurrence/remission by making direct correlations with immune responses and microbial populations on a longitudinal basis in individuals receiving sequential FMT, allowing for each individual to act as their own control.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Millan, Braden T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~